SR-17018: The Biased Mu-Opioid Agonist That Reverses Morphine Tolerance

SR-17018: The Biased Mu-Opioid Agonist That Reverses Morphine Tolerance

Evidence Snapshot SR-17018 is a synthetic, G protein-biased mu-opioid receptor (MOR) agonist developed by the Bohn laboratory at Scripps Research. In preclinical models, it produces sustained antinociception without tolerance, reverses pre-existing morphine tolerance, and prevents opioid withdrawal — a profile not observed with any clinically approved opioid. All data are preclinical (mouse models, in vitro receptor assays). No human trials exist.

Strong Disclaimer SR-17018 is not FDA approved. It has never been tested in humans. It is not a medication, not a supplement, and not available through any legal therapeutic channel. This article is an educational pharmacology review for researchers and clinicians tracking opioid innovation. Do not attempt to source, synthesize, or consume this compound.

TL;DR · What Makes SR-17018 Different

• G protein-biased MOR agonist — preferentially activates G protein signaling over β-arrestin-2 recruitment
• Sustained antinociception without tolerance — unlike morphine, fentanyl, and oxycodone
• Reverses established morphine tolerance — restores morphine analgesia in morphine-tolerant mice
• Prevents naloxone-precipitated withdrawal — suggests reduced physical dependence
• All data are preclinical — zero human studies; safety, efficacy, and abuse liability in humans are entirely unknown

---

1. What Is SR-17018?

SR-17018 is a synthetic small-molecule agonist at the mu-opioid receptor (MOR) — the same receptor targeted by morphine, oxycodone, fentanyl, and heroin. It was developed as part of a medicinal chemistry program at the Scripps Research Institute led by Dr. Laura M. Bohn, with the specific goal of producing a MOR agonist that preferentially activates G protein signaling while minimizing β-arrestin-2 recruitment [Grim et al., 2020; Pantouli et al., 2021].

The compound belongs to a class of "biased" or "functionally selective" opioid agonists. Unlike traditional opioids, which activate both major downstream signaling pathways at MOR (G protein and β-arrestin-2), biased agonists are designed to preferentially engage one pathway over the other. SR-17018 is one of the most G protein-biased MOR agonists described in the peer-reviewed literature [Gillis et al., 2020].

Chemical Identity

The exact chemical structure of SR-17018 has been disclosed in the peer-reviewed literature and patent filings. It is a non-morphinan scaffold — structurally distinct from morphine, fentanyl, and other classical opioid chemotypes — which contributes to its atypical pharmacological profile [Stahl et al., 2021].

---

2. Pharmacology: How Biased Agonism Works

The Two Signaling Pathways at MOR

When an opioid binds to the mu-opioid receptor, two major intracellular signaling cascades can be initiated:

1. G protein signaling (Gαi/o) — Inhibition of adenylyl cyclase → reduced cAMP → decreased neuronal excitability. This pathway is primarily responsible for analgesia (pain relief).

2. β-arrestin-2 recruitment — Receptor phosphorylation by GRKs (G protein-coupled receptor kinases) → β-arrestin-2 binding → receptor internalization, desensitization, and arrestin-dependent signaling. This pathway has been implicated in opioid side effects, including respiratory depression, constipation, and tolerance development [Bohn et al., 1999; Raehal et al., 2005].

The Biased Agonist Hypothesis

The "biased agonist hypothesis" holds that a MOR agonist which preferentially activates G protein signaling while minimizing β-arrestin-2 recruitment could produce analgesia with fewer side effects — less respiratory depression, slower tolerance development, and reduced constipation. This hypothesis was initially supported by β-arrestin-2 knockout mouse studies showing enhanced morphine analgesia with diminished side effects [Bohn et al., 1999; Raehal et al., 2005].

However, the hypothesis has become increasingly nuanced and contested. More recent studies suggest that:

• β-arrestin-2 deletion alone does not eliminate respiratory depression or constipation in all contexts [Kliewer et al., 2019; Kliewer et al., 2020]
• The "low intrinsic efficacy" of certain biased agonists — rather than pathway bias per se — may explain their improved side-effect profiles [Gillis et al., 2020]
• G protein signaling itself can contribute to adverse effects, including respiratory depression [Bachmutsky et al., 2021]

SR-17018 sits at the center of this scientific debate. Its unusual profile — sustained efficacy without tolerance — has challenged existing models of MOR signaling.

SR-17018's Signaling Profile

SR-17018 shows:

• Strong G protein activation — comparable to morphine in some assays
• Minimal β-arrestin-2 recruitment — among the lowest of any MOR agonist tested
• Atypical receptor phosphorylation — induces a phosphorylation pattern at MOR distinct from both morphine and fentanyl, followed by rapid dephosphorylation [Fritzwanker et al., 2021]
• Non-competitive agonist behavior — unlike morphine, SR-17018 does not compete with the antagonist naloxone for receptor binding in certain experimental paradigms [Stahl et al., 2021]

The non-competitive nature of SR-17018's binding is particularly significant: it suggests the compound may bind to a different receptor conformation or allosteric site, allowing it to activate MOR even in the presence of antagonists. This property may explain its ability to produce antinociception in morphine-tolerant animals — the receptors, though desensitized to morphine, may retain responsiveness to SR-17018 [Stahl et al., 2021].

---

3. Key Preclinical Findings

Study 1: Grim et al. (2020) — Reversal of Morphine Tolerance

Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho J-H, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM. A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology 45, 416–425 (2020). PMC6901606

This landmark study demonstrated SR-17018's most striking property:

• In morphine-tolerant mice (where morphine loses analgesic efficacy), SR-17018 retained full antinociceptive potency
• When SR-17018 was administered to morphine-tolerant mice and then withdrawn, naloxone did not precipitate withdrawal — suggesting reduced physical dependence
• SR-17018 produced antinociception comparable to morphine in opioid-naïve mice
• The compound showed no tolerance development with repeated dosing — unlike morphine, which loses efficacy over days of repeated administration

Study 2: Pantouli et al. (2021) — Comparison with Morphine and Oxycodone

Pantouli F, Grim TW, Schmid CL, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM. Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain. Neuropharmacology 186, 108439 (2021). PMC7887086

This head-to-head comparison in mouse models of inflammatory and neuropathic pain found:

• Morphine and oxycodone both produced rapid tolerance — analgesic efficacy dropped significantly within 5–7 days of repeated dosing
• SR-17018 produced sustained antinociception across the same time period with no loss of efficacy
• In a model of chronic inflammatory pain, SR-17018 was more effective than morphine at reversing pain-depressed behavior
• The study directly compared equi-effective doses, ruling out the possibility that SR-17018's favorable profile was due to under-dosing

Study 3: Stahl et al. (2021) — Non-Competitive Agonism

Stahl EL, Zhou L, Ehlert FJ, Bohn LM. G protein signaling-biased mu opioid receptor agonists that produce sustained antinociception without tolerance are noncompetitive agonists. (2021).

This mechanistic study revealed that SR-17018 behaves as a non-competitive agonist at MOR:

• SR-17018's binding is not displaced by naloxone in the same way as morphine
• The compound appears to bind to a distinct receptor conformation
• This non-competitive mode of action may explain the lack of tolerance: the receptor desensitization mechanisms that blunt morphine signaling may not affect SR-17018's binding site

Study 4: Gillis et al. (2020) — Low Intrinsic Efficacy Hypothesis

Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Christie MJ, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling 13(625), eaaz3140 (2020). PMID: 32234959

This study challenged the simple "G protein bias = safer" narrative by demonstrating that the improved side-effect profiles of SR-17018 and other biased agonists (oliceridine, PZM21) may be better explained by their low intrinsic efficacy for G protein activation rather than by β-arrestin bias alone. Key findings:

• SR-17018 has lower maximal G protein activation than morphine
• When assay signal windows were carefully controlled, the apparent "bias" of these compounds diminished
• The reduced side-effect profile correlated with low efficacy, not high bias
• This reframes the drug development conversation: partial MOR agonism with sufficient therapeutic window may be the real goal, not pathway selectivity

Study 5: Fritzwanker et al. (2021) — Atypical Receptor Phosphorylation

Fritzwanker S, Wawrzczak-Bargiela A, Kunze L, Keller M, Schulz S. SR-17018 stimulates atypical µ-opioid receptor phosphorylation and dephosphorylation. Frontiers in Pharmacology 12, 723560 (2021). PMC8348759

This molecular pharmacology study examined what happens to the MOR protein itself when activated by SR-17018:

• SR-17018 induces a unique phosphorylation barcode at the MOR C-terminus — different from the patterns produced by morphine, fentanyl, or DAMGO
• The receptor undergoes rapid dephosphorylation after SR-17018 stimulation
• This atypical phosphorylation/dephosphorylation cycle may explain why β-arrestin-2 is poorly recruited and why tolerance does not develop

---

4. Respiratory Depression and Safety

What the Preclinical Data Show

The question of whether SR-17018 causes less respiratory depression than conventional opioids is critical but the data are limited and mixed:

• Grim et al. (2020) reported that SR-17018 did not produce significant respiratory depression at analgesic doses in mice
• Gillis et al. (2020) found that the reduced respiratory depression from biased agonists correlated with low efficacy, not bias
• Pantouli et al. (2021) noted that SR-17018's safety margin (therapeutic index) appeared wider than morphine's in some but not all measures

A critical caveat: Respiratory depression data for SR-17018 come exclusively from rodent models. Rodent respiratory physiology differs from human in important ways, and compounds that appear safe in mice have produced fatal respiratory depression in humans. No conclusions about human respiratory safety can be drawn from available data.

What Is Fundamentally Unknown

SR-17018 has no human safety data whatsoever. The following are entirely unknown:

• Lethal dose in humans
• Respiratory effects at any dose
• Cardiac effects (QT prolongation, arrhythmia risk)
• Hepatotoxicity or nephrotoxicity
• Abuse potential and rewarding effects (conditioned place preference, self-administration)
• Cognitive or psychiatric effects
• Drug-drug interactions
• Long-term toxicity with repeated exposure
• Developmental or reproductive toxicity

Any human exposure would constitute an uncontrolled experiment with potentially fatal consequences.

---

5. Abuse Potential and Dependence

What Preclinical Data Suggest

• SR-17018 does not produce naloxone-precipitated withdrawal after repeated dosing in mice [Grim et al., 2020] — this is a striking finding that suggests reduced physical dependence compared to morphine
• The compound reverses morphine tolerance without causing withdrawal itself [Pantouli et al., 2021]
• No published conditioned place preference (CPP) or self-administration studies exist for SR-17018 — its abuse potential in animal models is not characterized

The "Low Abuse Potential" Hypothesis — Untested

While the lack of withdrawal signs and the sustained efficacy without tolerance have led some to hypothesize that SR-17018 might have lower abuse liability than conventional opioids, this hypothesis is entirely untested. Compounds that appear non-rewarding in preclinical models can produce euphoria and addiction in humans. Conversely, the non-competitive binding mode of SR-17018 could theoretically produce unique patterns of reinforcement that rodent models do not capture.

---

6. Where SR-17018 Fits in Opioid Drug Development

The Broader Biased Agonist Landscape

SR-17018 is one of several G protein-biased MOR agonists developed in recent years:

Why SR-17018 Matters — Scientifically

Even if SR-17018 never enters human trials, it has already contributed significantly to opioid pharmacology by:

1. Demonstrating that sustained MOR agonism without tolerance is possible — challenging the dogma that all MOR agonists inevitably produce tolerance
2. Revealing non-competitive agonism as a viable mechanism — providing a new structural template for drug design
3. Clarifying the relationship between efficacy, bias, and side effects — helping the field move beyond oversimplified "G protein bias = safe" narratives
4. Offering a tool compound for studying MOR signaling dynamics and receptor regulation in living systems

---

7. Limitations and Open Questions

Critical Gaps in Knowledge

1. No human data of any kind — pharmacokinetics, safety, efficacy, and subjective effects are entirely unknown
2. Long-term toxicity unknown — all animal studies involved short-term (days to weeks) exposure
3. Abuse potential uncharacterized — no published CPP or self-administration data in any species
4. Cross-tolerance with other opioids — partially studied but not fully characterized
5. Metabolism and excretion — not characterized; potential for toxic metabolites unknown
6. Species differences — MOR signaling differs between rodents and humans; effects may not translate
7. Selectivity for other receptors — full receptor screen not published; off-target effects unknown
8. Formulation and route — only studied via intraperitoneal injection in rodents; oral bioavailability unknown

The Translation Gap

The gap between promising rodent data and human clinical reality is particularly wide for opioid compounds. Many MOR agonists that appeared safer than morphine in preclinical models — including oliceridine and PZM21 — showed less dramatic advantages in human studies. The history of opioid drug development is littered with compounds that failed to translate their preclinical promise into clinical benefit.

---

8. Harm Reduction Context

What SR-17018 Is Not

• Not a treatment for opioid use disorder — it has never been studied for this indication
• Not a substitute for methadone or buprenorphine — these are FDA-approved, extensively studied medications with established safety profiles
• Not a "safe" opioid — its human safety profile is completely unknown
• Not available through any legitimate channel — any purported SR-17018 sold online is an unregulated research chemical of unknown purity and origin

If Encountered in Unregulated Markets

As with other research opioids (U-47700, isotonitazene, brorphine), novel MOR agonists can migrate from the laboratory into unregulated markets. Key harm reduction principles apply:

• Assume any unregulated powder sold as "SR-17018" is mislabeled, impure, or a different compound entirely
• Novel synthetic opioids have caused fatal overdoses at sub-milligram doses
• Naloxone may or may not effectively reverse SR-17018 — the non-competitive binding profile raises theoretical questions about naloxone efficacy
• Fentanyl test strips will not detect SR-17018
• The combination of unknown potency and unknown naloxone response creates a uniquely dangerous profile

---

References

1. Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho J-H, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM. A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology 45, 416–425 (2020). PMC6901606

2. Pantouli F, Grim TW, Schmid CL, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM. Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain. Neuropharmacology 186, 108439 (2021). PMC7887086

3. Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Christie MJ, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling 13(625), eaaz3140 (2020). PMID: 32234959

4. Stahl EL, Zhou L, Ehlert FJ, Bohn LM. G protein signaling-biased mu opioid receptor agonists that produce sustained antinociception without tolerance are noncompetitive agonists. (2021).

5. Fritzwanker S, Wawrzczak-Bargiela A, Kunze L, Keller M, Schulz S. SR-17018 stimulates atypical µ-opioid receptor phosphorylation and dephosphorylation. Frontiers in Pharmacology 12, 723560 (2021). PMC8348759

6. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286(5449), 2495–2498 (1999). PMID: 10617462

7. Raehal KM, Walker JKL, Bohn LM. Morphine side effects in β-arrestin 2 knockout mice. Journal of Pharmacology and Experimental Therapeutics 314(3), 1195–1201 (2005). PMID: 15917413

8. Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Williams N, Arora R, Christie MJ, Schulz S. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nature Communications 10, 367 (2019). PMC6342992

9. Kliewer A, Gillis A, Hill R, Schmidel F, Bailey C, Kelly E, Henderson G, Christie MJ, Schulz S. Morphine-induced respiratory depression is independent of β-arrestin-2 signalling. British Journal of Pharmacology 177(13), 2923–2931 (2020). PMC7280015

10. Cornelissen JC, De Carvalho MM, Guzzo PR, Negus SS. Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys. Frontiers in Pharmacology 12, 657124 (2021). PMC8266741

11. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. Journal of Pharmacology and Experimental Therapeutics 344(3), 708–717 (2013). PMID: 23300227

12. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016). PMC5164932

13. Bachmutsky I, Wei XP, Kish E, Yackle K. Opioids depress breathing through two small brainstem sites. eLife 10, e62554 (2021). PMC7886324

14. Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, Cameron MD, Bannister TD, Bohn LM. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 171(5), 1165–1175.e13 (2017). PMC5731252

15. Bateman JT, Saunders DC, Metzger MB, Lee H, Kelly MJS. Evaluation of G protein bias and β-arrestin 2 signaling in opioid-induced respiratory depression. eLife 10, e62554 (2021). PMC8560383

---

Last updated: 2026-06-30. This article will be updated as new preclinical or clinical data emerge. No human studies of SR-17018 are registered on ClinicalTrials.gov as of this date.